<DOC>
	<DOCNO>NCT02043860</DOCNO>
	<brief_summary>In phase I trial , patient multiple myeloma receive standard high dose melphalan autologous stem cell rescue . In addition pre-transplant conditioning include target total marrow irradiation ( TMI ) . This conventional 3+3 phase I trial increase dose TMI maximum tolerate dose ( MTD ) reach . Initial patient enrol receive low possible dose 3Gy . Maximum dose 12Gy .</brief_summary>
	<brief_title>Total Marrow Irradiation With High Dose Melphalan Prior Autologous Transplant Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Patients meet criterion symptomatic myeloma 2 . Patients must high intermediate risk disease progression define one follow criterion : 2.1 ISS stage 2 3 disease 2.2 Abnormal metaphase cytogenetics 2.3 Presence FISH abnormality aside hyperdiploidy 3 . Patients receive least 2 cycle systemic treatment kind precede 12 month 4 . Patient age 1875 year time enrollment 5 . Karnofsky performance status ≥70 6 . Cardiac function : LVEF &gt; 40 % 7 . Hepatic : Bilirubin &lt; 2x upper limit normal ALT AST &lt; 2.5x upper limit normal 8 . Renal : Creatinine clearance ≥30mL/min , estimate calculated 9 . Pulmonary : DLCO , FEV1 , FVC &gt; 50 % predict ( correction hemoglobin ) 1 . Patients diagnosis plasma cell leukemia 2 . Patients myeloma disease progression prior enrollment 3 . Patients truly non secretory myeloma ( patient light chain disease eligible ) 4 . Pregnant breastfeed 5 . Uncontrolled viral , fungal bacterial infection Note : Infection permit evidence response medication . Eligibility HIV infect patient determined casebycase basis . 6 . Patients undergone prior allograft autologous transplant 7 . Prior solid organ transplant 8 . Patients receive prior radiation 20 % bone marrow contain area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>High Risk</keyword>
	<keyword>Intermediate Risk</keyword>
	<keyword>Symptomatic</keyword>
</DOC>